4 Jan 2021 15:05
4 January 2021
THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.
FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN SENSYNE HEALTH PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.
Sensyne Health plc
("Sensyne Health" or the "Company")
Result of Open Offer
Oxford, UK - 4 January 2021: Sensyne Health plc (LSE: SENS), the UK clinical AI company, announces that it has conditionally raised total gross proceeds of approximately £2.5 million through the Open Offer which was announced on 8 December 2020.
Accordingly, the Company has conditionally raised total gross proceeds of approximately £27.5 million (before expenses) in aggregate by way of the Placing and Subscription (which were also announced on 8 December 2020), and the Open Offer.
As the Open Offer was oversubscribed, the Directors of the Company will use their discretion to undertake a scaling back process that will have regard to those Qualifying Shareholders who were not offered the opportunity to participate in the Placing.
Application has been made to the London Stock Exchange for the admission of 30,513,341 New Shares to trading on AIM ("Admission"). This comprises (i) 27,373,337 Placing Shares; (ii) 404,440 Subscription Shares; and (iii) 2,735,564 Open Offer Shares. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares. Admission is expected to occur on or around 5 January 2021.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 8 December 2020.
For further information, please contact:
Sensyne Health plc | ||
Lord (Paul) Drayson PhD FREng | Chief Executive Officer | T: +44 (0) 330 058 1845 |
Michael Norris | Chief Financial Officer | |
Peel Hunt LLP | Dr Christopher Golden | T: +44 (0) 207 418 8900 |
Joint Bookrunner | Oliver Jackson | |
Jock Maxwell Macdonald | ||
Liberum Capital Ltd | Bidhi Bhoma | T: +44 (0) 20 3100 2000 |
Joint Bookrunner | Euan Brown | |
Consilium Strategic | Mary-Jane Elliott | T: +44 (0) 77 0286 8207 |
Communications | Sukaina Virji | |
Davide Salve |
About Sensyne
Sensyne Health (AIM: SENS) is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS guidelines, UK data protection law and applicable regulatory guidance. Sensyne Health is based in the Schrödinger Building in Oxford Science Park. For more information, please visit: www.sensynehealth.com